{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"199.500","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,540,975,898","primaryexch":"香港交易所","ric":"6160.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"B","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BVDKGC7","am":"1.62","iv":"","ew_strike":"","as":"196.200","geographic_focus":null,"incorpin":"瑞士","etp_baseCur":null,"ew_amt_os":"","bd":"196.000","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"103.100","shares_issued_date":"2025年9月11日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"歐雷強","underlying_ric":"6160.HK","hi52":"213.000","issuer_name":"百濟神州有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"190.000","mkt_cap":"302.33","f_aum_hkd":null,"ew_sub_per_to":"","ls":"196.200","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-3.700","aum":"","issued_shares_class_B":null,"vo":"8.35","secondary_listing_flag":false,"listing_date":"2018年8月8日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"百濟神州有限公司","nm_s":"百濟神州","sym":"6160","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.100","strike_price":"","summary":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球腫瘤學公司，致力於為全球癌症患者研發新療法。該公司產品組合涵蓋血液學和實體瘤，致力於開發多樣化的新型療法。其產品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一種口服的布魯頓酪氨酸激酶(BTK)小分子抑製劑。Tevimbra是一種人源化免疫球蛋白G4（IgG4）抗程序性細胞死亡蛋白1（PD-1）單克隆抗體，具有高親和力和對PD-1的結合特異性。Tevimbra旨在最大限度地減少與巨噬細胞上Fc-γ（Fcy）受體的結合，幫助人體免疫細胞檢測和對抗腫瘤。該公司正在開發的產品線包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","op":"192.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>銅鑼灣<br/>希慎道33號<br/>利園1期19樓1901室","pc":"-1.85","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"USD","hdr":false,"launch_date":"","hc":"199.900","isin":"CH1391448177","moneyness":""}},"qid":"1759073981499"}
